Zanubrutinib shows durable efficacy in CLL/SLL with 17p deletions, according to 5-year SEQUOIA trial data.

Adjuvant nivolumab offered sustained survival benefits in resected esophageal/GEJ cancer post chemoradiation, with PD-L1 ...

Camizestrant plus CDK4/6 inhibition improved progression-free survival when given to patients with ESR1-mutant ER+/HER2– ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

In the phase 3 PANOVA-3 trial, patients who underwent tumor-treating fields therapy had extended overall survival vs standard ...

Less inflammatory diets were linked to improved overall survival in stage III colon cancer, and physical activity showed ...

A 3-year structured exercise program significantly improved DFS and OS in stage II/III CRC, reducing recurrence by 28% and ...

The next-generation KRAS G12C inhibitor MK-1084 showed promising efficacy and safety as a single agent and in combinations ...

Suneel Kamath, MD, presented an analysis of federal cancer research funding disparities and their ripple effects on care delivery and outcomes.

Erin Cobain, MD, discusses findings from a study exploring the differences in diagnosis and treatment of high-risk breast cancer in Black and White patients.

A molecular test identified patients with high-risk early lung cancer who significantly benefitted from adjuvant chemotherapy ...

DNA methylation, RTK pathway changes, and KRAS amplifications may drive resistance to sotorasib plus panitumumab in KRAS G12C ...